• Feature ArticlesFeature Articles

    Ambiguity from FDA Stunts Growth in the US, While Innovation Flourishes in Europe

    Editor's note: RAPS is a neutral, non-lobbying organization. The views expressed in this Perspectives piece by Chris Velis, CEO and chairman of MedCap Advisors, are those of the author. We hope this article will stimulate conversation, and we invite you to discuss it in the Regulatory Open Forum on Regulatory Exchange , our private social media community for RAPS members. Current State of Affairs Inconsistency and ambiguity in the US Food and Drug Administration's (F...